Home » York Man Federally Sentenced for Prescription Drug Fraud Conspiracy
York Man Federally Sentenced for Prescription Drug Fraud Conspiracy
FDA.gov
PharmaManufacturing.com
05/20/2010
Dennis C. Pfannenschmidt, United States Attorney for the Middle District of Pennsylvania, announced today that Curtis L. Hess, age 49, of York, Pennsylvania, was sentenced yesterday to a 16-month term of imprisonment by United States District Court Senior Judge Edwin M. Kosik for introducing misbranded drugs into interstate commerce with the intent to defraud and mislead. Judge Kosik further ordered him to pay a $18,000 fine. Hess also forfeited $76,291.80.
According to U.S. Attorney Pfannenschmidt, beginning in January 2005 and continuing until April 2006, Hess--through his company, Hess Rx Distribution, L.L.C.--smuggled prescription drugs from Canada into the United States. The drugs, although having similar names and active ingredients to drugs available in the United States, were not FDA-approved for marketing and distribution in the United States. Hess distributed these drugs to pharmacies throughout the country.
Patients who received these drugs from pharmacies were unaware that they had been smuggled into the United States. Before Hess’ operation was shut down by FDA agents, he had distributed approximately $475,000 worth of unapproved prescription pharmaceuticals.
Hess was charged in September 2009 and later pleaded guilty.
“This investigation, prosecution and sentencing demonstrates that the FDA takes seriously the threat posed by those individuals who operate outside the secure pharmaceutical supply chain by illegally importing and distributing non-FDA approved products to unsuspecting US consumers,” said Thomas P. Doyle, Special Agent in Charge, FDA’s Office of Criminal Investigations, Metro Washington Field Office. “Those who engage in such criminal conduct will be held liable.”
This case was investigated by the Food and Drug Administration’s Office of Criminal Investigations and prosecuted by Assistant United States Attorney Joseph J. Terz.
More News:
-
05/17/2012
Study: US Clears Drugs Faster Than Europe, CanadaFrom WSJ.com
Researchers say the U.S. approved more new medicines in less time than Europe and Canada in the last decade, challenging long-standing criticisms that the Food and Drug Administration lags behind its peers in clearing important new drugs.
-
05/10/2012
Ex-Sanofi Chemist Sentenced To 18 Months For Trade Secrets TheftFrom WSJ.com
A 30-year-old former research chemist for pharmaceutical firm Sanofi was sentenced to 18 months in prison for stealing Sanofi trade secrets and making them available through another company, the U.S. Department of Justice said.
-
04/27/2012
Novo Nordisk Expanding U.S. Workforce 15 Percent
Most new positions are in sales and management, but manufacturing jobs will be added in Clayton, N.C.
-
04/26/2012
AstraZeneca’s Brennan to Retire; Lowth Named Interim CEOFrom Bloomberg.com
AstraZeneca Chief Executive Officer David Brennan will retire from his post, ending a six- year tenure after repeated failures in drug development left investors skeptical of the company’s earnings prospects.
-
04/19/2012
Congress Pushing to Allow Generic Drug Manufacturers to Make Label ChangesFrom Pharmalot
The U.S. Congress has introduced bills that would allow generic makers to make updates to labels as new safety and efficacy information becomes available.
- 04/18/2012 GSK Shifts to Unassigned Seating in RTP Offices
- 04/17/2012 Amgen CEO Comes Clean: I Was Arrogant and an Awful Listener
- 04/16/2012 Product News: Growth Direct Systems for Environmental Monitoring and Sterility
-
04/12/2012
J&J Fined $1.2 Billion in Drug CaseFrom NYTimes.com
A judge in Arkansas ordered Johnson & Johnson and a subsidiary to pay more than $1.2 billion in fines on Wednesday, a day after a jury found that the companies had minimized or concealed the dangers associated with an antipsychotic drug.
- 04/11/2012 Humira Set to Become World's Top-Selling Drug
- All news »
Get Connected Now!
- Featured White Papers

Print page